溴化六甲铵
中文名称:
溴化六甲铵
中文同义词:
溴化六甲铵;六甲溴铵;溴化六甲双铵;溴化六烃季铵;溴化六烃季铵C6;六次甲基双-1,6-溴化三甲铵;六亚甲基-1,6-双(三甲基溴化铵);六亚甲基-1,6-双溴化三甲铵
英文名称:
HEXAMETHONIUM BROMIDE
英文同义词:
gangliostat;hexamethioniumbromide;hexamethylenebis(trimethyl-ammoniudibromide;hexameton;hexoniumdibromide;simpatoblock;Methobromine;Hexamethonium bromide,Hexane-1,6-bis(trimethylammonium bromide), N,N,N,N′,N′,N′-Hexamethylhexamethylenediammonium dibromide
CAS号:
55-97-0
分子式:
C12H30Br2N2
分子量:
362.19
EINECS号:
200-249-7
相关类别:
小分子抑制剂;催化剂;化工中间体;有机化工原料;中间体;化工原料;Ammonium Bromides (Quaternary);Quaternary Ammonium Compounds
Mol文件:
55-97-0.mol
熔点
~285 °C (dec.)
储存条件
Inert atmosphere,Room Temperature
形态
Crystalline Powder and Agglomerates
颜色
White
PH值
pH (20g/l, 25℃) : 4.5～6.5
Merck
14,4688
BRN
3715749
InChIKey
FAPSXSAPXXJTOU-UHFFFAOYSA-L
CAS 数据库
55-97-0(CAS DataBase Reference)
EPA化学物质信息
1,6-Hexanediaminium, N1,N1,N1,N6,N6,N6-hexamethyl-, bromide (1:2) (55-97-0)
生物活性
Hexamethonium Dibromide是一种神经中枢中选择性的神经元烟碱型AChR选择性拮抗剂。
靶点
Target Value
Dopamine subtype 2 receptor
AChR
Target
Value
Dopamine subtype 2 receptor
AChR
体外研究
Hexamethonium Bromide能有效抵抗Ach和卡巴胆碱(CCh)对大鼠肩胛舌骨肌终板振幅的响应，EC50分别为300 μM和100 μM。0.6 μM 筒箭毒碱存在下，Hexamethonium Bromide (50-200 μM)使神经诱发的终板电流(e.p.cs)的振幅增加。在大鼠肌肉匀浆中，Hexamethonium Bromide也是乙酰胆碱酯酶活性的弱抑制剂，EC50为1.5 mM。在大鼠一侧膈肌中，Hexamethonium Bromide (200 μM)降低终板电流(e.p.cs) (降低~25%)和微终板电流(m.e.p.cs) (降低~20%)衰变的时间常数。在低频刺激(0.5-2 Hz)下，Hexamethonium Bromide (200 μM)增加30-40% e.p.c.量子含量。
体内研究
Hexamethonium Bromide (0.2-25 mg/kg; i.v.) significantly reduces the renal sympathetic nerve activity (RSNA), mean arterial pressure (MAP) and heart rate (HR) in the Wistar rats and the spontaneously hypertensive rats (SHRs).
Hexamethonium Bromide (0.2-1.0 mg/kg; i.v.) treatments show no significant differences in the RSNA, MAP or HR between Wistar rats and SHRs.
Hexamethonium Bromide (5.0-25 mg/kg; i.v.) results in a greater reduction in the RSNA and MAP in SHRs compared with Wistar rats.
Animal Model: Male normotensive Wistar rats (280-320 g), SHRs
Dosage: 0.2 mg/kg, 1.0 mg/kg, 5.0 mg/kg, 25 mg/kg
Administration: Intravenous injection
Result: Significantly reduced the RSNA, MAP and HR in the Wistar rats and the SHRs.
Animal Model:
Male normotensive Wistar rats (280-320 g), SHRs
Dosage:
0.2 mg/kg, 1.0 mg/kg, 5.0 mg/kg, 25 mg/kg
Administration:
Intravenous injection
Result:
Significantly reduced the RSNA, MAP and HR in the Wistar rats and the SHRs.
安全说明
22-24/25
WGK Germany
2
RTECS号
BQ8575000
TSCA
Yes
海关编码
29239000
